Literature DB >> 10384105

CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation.

M J Deeths1, R M Kedl, M F Mescher.   

Abstract

CD8+ T cells stimulated in vitro with anti-TCR mAb and B7-1 or ICAM-1 produce IL-2 and clonally expand. Effector function is acquired within 3 days, but proliferation ceases and the cells begin to die by apoptosis. Stimulation in vivo with B7-1-expressing allogeneic tumor results in the same sequence of events with a comparable time course. In both cases, the cells become anergic within 3 or 4 days of responding; they can no longer respond by producing IL-2 and proliferating, but can still be stimulated to proliferate in response to exogenous IL-2. This activation-induced nonresponsiveness (AINR) is not simply a consequence of ongoing cell death; cytokines that promote survival (IL-7 or IFN-alpha) or proliferation (human IL-2) do not restore the ability to produce IL-2 in response to costimulation. Although similar to the anergy described for CD4+ T cell clones, AINR differs in that it results from an initial stimulation with both signal 1 and signal 2. AINR appears to be an aspect of the normal differentiation of fully stimulated CD8+ T cells. It is probably important in regulating CTL responses; it limits the initial T helper-independent response and converts it to a response that requires T cell help to be sustained and further expanded. When the initial helper-independent response is not sufficient to clear Ag, and if help is not available, AINR likely results in tolerance to the Ag.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10384105

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance.

Authors:  Yeonseok Chung; Dong-Hyeon Kim; Seung-Ho Lee; Chang-Yuil Kang
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

Review 2.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

3.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

4.  Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes.

Authors:  Michael Uhlin; Maria G Masucci; Victor Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-15       Impact factor: 11.205

Review 5.  Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation.

Authors:  Matthew F Mescher; Pujya Agarwal; Kerry A Casey; Christopher D Hammerbeck; Zhengguo Xiao; Julie M Curtsinger
Journal:  Semin Immunol       Date:  2007-03-26       Impact factor: 11.130

6.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

7.  Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production.

Authors:  Shaun O'Brien; Rajan M Thomas; Gerald B Wertheim; Fuqin Zhang; Hao Shen; Andrew D Wells
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

Review 8.  Shaping successful and unsuccessful CD8 T cell responses following infection.

Authors:  Maureen A Cox; Allan J Zajac
Journal:  J Biomed Biotechnol       Date:  2010-03-31

9.  IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.

Authors:  Mary Zimmerman; Dafeng Yang; Xiaolin Hu; Feiyan Liu; Nagendra Singh; Darren Browning; Vadivel Ganapathy; Phillip Chandler; Divaker Choubey; Scott I Abrams; Kebin Liu
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

Review 10.  A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.